Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Echevarria

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
AIDS Research and Therapy|September 10, 2010
Mobile learning for HIV/AIDS healthcare worker training in resource-limited settingsMaria Zolfo, David Iglesias, Carlos Kiyan, et al.
The American Journal of Tropical Medicine and Hygiene|March 3, 2005
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasisEllen M Andersen, Maria Cruz-Saldarriaga, Alejandro Llanos-Cuentas, et al.
AIDS Research and Human Retroviruses|February 4, 2015
A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the CaribbeanMark J Giganti, Paula M Luz, Yanink Caro-Vega, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 31, 2006
Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV-1 infectionCésar Cárcamo, Thomas Hooton, Noel S Weiss, et al.
Journal of the International AIDS Society|November 14, 2014
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysisCynthia Brinson, Jacob Lalezari, Latiff H Gulam, et al.
Journal of the International AIDS Society|November 14, 2014
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysisJacob Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Lancet (London, England)|August 30, 2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America NetworkMarcelo Wolff, Bryan E Shepherd, Claudia Cortés, et al.
Plos One|October 8, 2013
Medication possession ratio predicts antiretroviral regimens persistence in PeruJorge L Salinas, Jorge L Alave, Andrew O Westfall, et al.
Plos Neglected Tropical Diseases|March 7, 2022
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New WorldLiliana López, Braulio Valencia, Fiorela Alvarez, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
AIDS Research and Therapy|September 10, 2010
Mobile learning for HIV/AIDS healthcare worker training in resource-limited settingsMaria Zolfo, David Iglesias, Carlos Kiyan, et al.
The American Journal of Tropical Medicine and Hygiene|March 3, 2005
Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasisEllen M Andersen, Maria Cruz-Saldarriaga, Alejandro Llanos-Cuentas, et al.
AIDS Research and Human Retroviruses|February 4, 2015
A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the CaribbeanMark J Giganti, Paula M Luz, Yanink Caro-Vega, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 31, 2006
Randomized controlled trial of zinc supplementation for persistent diarrhea in adults with HIV-1 infectionCésar Cárcamo, Thomas Hooton, Noel S Weiss, et al.
Journal of the International AIDS Society|November 14, 2014
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysisCynthia Brinson, Jacob Lalezari, Latiff H Gulam, et al.
Journal of the International AIDS Society|November 14, 2014
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysisJacob Lalezari, Gulam H Latiff, Cynthia Brinson, et al.
Lancet (London, England)|August 30, 2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean-Michel Molina, Jaime Andrade-Villanueva, Juan Echevarria, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2016
Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America NetworkMarcelo Wolff, Bryan E Shepherd, Claudia Cortés, et al.
Plos One|October 8, 2013
Medication possession ratio predicts antiretroviral regimens persistence in PeruJorge L Salinas, Jorge L Alave, Andrew O Westfall, et al.
Plos Neglected Tropical Diseases|March 7, 2022
A phase II multicenter randomized study to evaluate the safety and efficacy of combining thermotherapy and a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the New WorldLiliana López, Braulio Valencia, Fiorela Alvarez, et al.
Pageof 3